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Abstract
There is increasing evidence of molecular and cellular links between Alzheimer’s disease (AD) and prion diseases. The
cellular prion protein, PrP
C, modulates the post-translational processing of the AD amyloid precursor protein (APP), through
its inhibition of the b-secretase BACE1, and oligomers of amyloid-b bind to PrP
C which may mediate amyloid-b
neurotoxicity. In addition, the APP intracellular domain (AICD), which acts as a transcriptional regulator, has been reported
to control the expression of PrP
C. Through the use of transgenic mice, cell culture models and manipulation of APP
expression and processing, this study aimed to clarify the role of AICD in regulating PrP
C. Over-expression of the three major
isoforms of human APP (APP695, APP751 and APP770) in cultured neuronal and non-neuronal cells had no effect on the level
of endogenous PrP
C. Furthermore, analysis of brain tissue from transgenic mice over-expressing either wild type or familial
AD associated mutant human APP revealed unaltered PrP
C levels. Knockdown of endogenous APP expression in cells by
siRNA or inhibition of c-secretase activity also had no effect on PrP
C levels. Overall, we did not detect any significant
difference in the expression of PrP
C in any of the cell or animal-based paradigms considered, indicating that the control of
cellular PrP
C levels by AICD is not as straightforward as previously suggested.
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Introduction
Alzheimer’s disease (AD) and prion diseases fall within the
spectrum of neurodegenerative diseases which are causally linked
to misfolded and aggregated proteins. Due to similarities in various
structural elements and proteolytic processing events involving the
major proteins involved in these diseases, potential links and
parallels in both disease mechanisms and possible therapeutic
avenues have been proposed [1,2,3,4]. Increasingly, recent studies
have shown more direct molecular links between AD and prion
diseases, and the proteins at the centre of these diseases; namely
the amyloid precursor protein (APP) and its proteolytic cleavage
product the amyloid-b (Ab) peptide which deposits as plaques in
the AD brain, and the normal cellular prion protein (PrP
C) and the
disease-associated isoform PrP
Sc, which accumulates in prion
diseases. A substantive molecular link was provided when PrP
C
was shown to modulate production of Ab from wild type APP,
through an interaction with the b-secretase BACE1 [5], later
demonstrated to be a mechanism for altered trafficking and
localisation of BACE1 resulting in reduced Ab production [6].
Additionally, several groups have now presented evidence that
PrP
C can bind oligomeric forms of Ab [7,8,9,10], although there is
conflicting data regarding the downstream consequences of this
binding. Some results suggest that Ab oligomer synaptic toxicity is
mediated through its binding to PrP
C [7,11,12], whereas others
have reported that Ab oligomer neurotoxicity is independent of
PrP
C expression [8,9]. Whilst perhaps explained by methodolog-
ical differences, these opposing results underscore the complexity
in the possible interactions between these two key proteins and
diseases.
In addition to Ab, a number of other proteolytic fragments are
generated from APP. Cleavage of the full length APP by either a-
secretase or BACE1 produces large soluble N-terminal ectodo-
mains, and C-termimal membrane-bound stubs, denoted C83 and
C99, respectively. Both C83 and C99 can be cleaved by the c-
secretase complex to produce the APP intracellular domain
(AICD) [13]. This latter fragment appears to act as a transcrip-
tional regulator after forming a complex with Fe65 and Tip60
[14]. In particular AICD has been shown to regulate the
expression of the Ab degrading enzyme neprilysin [15,16].
Interestingly, it appears to be only the AICD produced from the
combined action of BACE1 and c-secretase on APP that is
transcriptionally active [17,18,19].
There are three major isoforms of APP expressed in the brain,
APP695, APP751 and APP770, which are produced via alternative
splicing of the single mRNA [20]. Of the three, APP695 is the
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AICD produced from the b- and c-secretase cleavage of APP695,
and not that produced from the other two isoforms, is
transciptionally active as assessed by its ability to upregulate
neprilysin expression [19]. This transcriptionally active AICD was
only produced in neuronal (SH-SY5Y and N2a) cell lines and was
not functional in non-neuronal human embryonic kidney
(HEK293) cells [19]. Further, AICD produced from the familial
AD associated Swedish mutant form of APP695, known to be
subject to increased BACE1 cleavage compared to wild type
APP695 [21], was more transcriptionally active relative to wild type
APP695 [19].
The molecular and cellular links between APP and PrP
C were
extended recently when PrP
C expression was reported to be
regulated by AICD [22]. Overexpression of APP751 in HEK cells
triggered a significant increase in PrP
C immunoreactivity, while a
reduction in PrP
C was observed in APP deficient fibroblasts. The
c-secretase inhibitor DAPT significantly reduced PrPC levels in
primary neurons, implicating a role for AICD in controlling the
expression of PrPC [22]. The aim of the present study was to
clarify the role of AICD in the regulation of PrP
C and to
specifically determine whether, similar to the control of neprilysin
expression [19], there was an APP isoform effect.
Results
Over-expression of APP does not alter endogenous PrP
C
protein expression
Initially we sought to replicate the findings of Vincent et al. [22]
by expressing APP751 in HEK cells. In addition, we looked to
advance this research by determining whether the control of PrP
C
expression by AICD was specific to a particular APP isoform.
HEK cells stably over-expressing either APP695, APP751 or
APP770, alongside a vector only control were assessed for total
cell associated PrP
C and APP protein levels by western blotting
(Fig. 1A and B). Surprisingly, in contrast to previously published
results [22], although there was a significant 2–3-fold increase in
APP in the cells transfected with any of the three APP isoforms,
there was no significant difference in PrP
C level in any of the APP
isoform expressing cells when compared to the Hyg vector-only
controls.
We have recently shown that transcriptionally active AICD is
only produced by the BACE1 and c-secretase cleavage of the
Figure 1. Over-expression of APP isoforms in HEK cells does not alter endogenous PrP
C. (A) Representative western blot of APP and PrP
C
(antibody 3F4) in HEK cells stably transfected with either the vector alone (Hyg) or one of the APP isoforms (APP695, APP751, APP770), and subsequent
b-actin staining to allow adjustments for equal protein loading. Approximate molecular weights (kDa) are indicated. (B) Quantification of APP and
PrP
C protein levels expressed relative to Hyg control cells (dashed line). Data from 4 independent experiments. Statistical analysis by one way ANOVA
with Dunnett’s post test comparison to the Hyg cells, ***p,0.001, **p,0.01, n.s. not significant.
doi:10.1371/journal.pone.0031754.g001
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negative result observed in the non-neuronal HEK cells, we
utilized mouse neuronal N2a cells over-expressing human APP695
or APP751 to again assess total PrP
C and APP protein levels
(Fig. 2A and B). Despite a significant 2.5-fold increase in APP
expression in the N2a cells transfected with the cDNAs encoding
either APP695 or APP751, there was no difference in endogenous
PrP
C levels when comparing the APP over-expressing cells with
each other or the vector only controls.
To further examine the effect of APP over-expression on PrP
C
levels, two transgenic mouse models were investigated. PrP
C and
APP protein levels were evaluated in brain homogenates from I5
mice which over-express wild type human APP, J20 mice which
over-express human APP containing the Swedish/Indiana familial
AD mutations [23] and non-transgenic matched genetic back-
ground control mice (Fig. 3A and B). Despite a significant 2.8 -fold
increase in APP in the transgenic I5 mice, as compared to the non-
transgenic mice, there was no difference in brain PrP
C levels.
Figure 2. Over-expression of APP isoforms in N2a cells does not alter endogenous PrP
C. (A) Representative western blot of APP and PrP
C
(antibody 6H4) in N2a cells stably transfected with either the vector alone (Hyg) or one of the APP isoforms (APP695, APP751), and subsequent b-actin
staining. Approximate molecular weights (kDa) are indicated. (B) Quantification of APP and PrP
C protein levels expressed relative to Hyg control cells
(dashed line). Data from 3 independent experiments. Statistical analysis by one way ANOVA with Dunnett’s post test comparison to the Hyg cells,
*p,0.05, n.s. not significant.
doi:10.1371/journal.pone.0031754.g002
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reinforced this conclusion. Collectively these over-expression
experiments indicate that control of PrP
C expression does not
appear to involve AICD in either cell-based or transgenic animal
paradigms.
Reduction of AICD production through APP gene
silencing or c-secretase inhibition does not alter
expression of endogenous PrP
C
In light of the above results, we considered whether the level of
AICD required to regulate PrP
C expression in the cell lines or the
transgenic mice were already maximal from the endogenous APP,
such that the AICD produced from the over-expressed APP was
not having any additional affect on PrP
C expression. Thus we
sought to investigate a possible role for endogenous AICD in the
control of PrP
C expression. First, to reduce endogenous APP levels
and thereby remove the substrate for AICD production, N2a cells
were treated with siRNA against murine APP. Cells were
harvested, lysed and PrP
C and APP levels measured by western
blotting (Fig. 4A and B). After directed siRNA treatment there was
a significant 70% decrease in total APP levels (endogenous AICD
level is below the limits of detection by immunoblot; data not
shown). However, the amount of PrP
C remained unchanged
following siRNA knockdown of endogenous APP.
In order to test further for a possible involvement of endogenous
AICD in controlling PrP
C expression, both HEK and N2a cells
were treated with DAPT, a cell permeable c-secretase inhibitor.
Again, whole cell lysates were assessed for PrP
C and APP
expression, as well as the levels of C83 and C99, by western
blotting (Fig. 5A and B). Although DAPT treatment inhibited c-
secretase activity, as shown by the significantly increased C83 and
C99 levels (9.4-fold in the HEK cells and 17.8-fold in the N2a
cells), there was no difference in endogenous PrP
C protein levels in
the DAPT treated cells as compared to the untreated cells (Fig. 5C
and D). Together these results indicate that in both a neuronal and
a non-neuronal cell line, endogenous AICD is also not involved in
the control of PrP
C protein expression.
Figure 3. Unaltered PrP
C protein levels in transgenic mice over-expressing human wild type or familial AD mutant APP. (A) Western
blot of APP and PrP
C (antibody 6D11) in I5 (n=3) and J20 (n=2) transgenic, and age-matched non-transgenic control, mouse brain homogenates,
with membrane re-probing for b-actin. Approximate molecular weights (kDa) are indicated. (B) Quantification of APP and PrP
C protein levels
expressed relative to the control mice (dashed line). Error bars represent 6 SD. Statistical analysis by unpaired t-test, **p,0.01, n.s. not significant.
doi:10.1371/journal.pone.0031754.g003
PrPC Is Not Regulated by AICD
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31754Discussion
Similarities in the pathogenesis of the protein-misfolding
neurodegenerative illnesses, especially AD and prion diseases,
and possible connections between these diseases have long been
contemplated [1,2,3,4]. Elucidation of any functional links
between these diseases is an important research goal, with
determination of the most appropriate protein or process to target
for development of therapeutics being paramount. Links in the
pathologies of AD and prion diseases have been determined, with
various reports of AD features in prion disease brains [24,25,26],
and PrP
C localised in Ab plaques in AD brain [27,28]. In addition,
a polymorphism at codon 129 of the prion protein gene, known to
influence susceptibility to sporadic and iatrogenic human prion
disease [29,30], may also influence susceptibility and the
pathophysiology of AD [31,32,33]. Interestingly there is some
indication of a more direct interaction between Ab and PrP
Sc, with
the finding of an acceleration and exacerbation of both AD and
prion disease pathologies in animals engineered to have both of
these diseases, and enhanced protein misfolding due to cross-
seeding events stimulating oligomerization in vitro [34]. This
propensity for cross-seeding highlights the importance for a more
complete understanding of interactions between these key proteins
and any resultant downstream consequences.
Recent studies have provided evidence of direct interactions
between the proteins central to AD and prion diseases. Various
studies have determined that the cellular prion protein can act as a
receptor for Ab, with Ab oligomers binding to PrP
C with high
affinity, although there are conflicting views as to the physiological
significance of this binding. Some results suggest that Ab synaptic
toxicity is mediated through its binding to PrP
C [7,11,12], which
specifically impacts on spatial learning and memory in vivo [35],
whereas others have reported that Ab oligomer neurotoxicity
occurs independently [8,9]. Confounding the relationship between
these key proteins, and in apparent contrast to PrP
C mediating Ab
neurotoxicitiy, PrP
C has been shown to decrease production of Ab
from wild type APP through its interaction with the b-secretase
BACE1 [5]. This interaction, mapped to the BACE1 pro-domain,
leads to slowed BACE1 trafficking following exit from the ER,
thereby increasing its localization in the trans-Golgi network and
reducing levels at the cell surface and consequently in endosomes
where APP b-cleavage occurs [6]. Importantly, these studies also
ascertained links in the pathology of AD and prion diseases. It was
found that human prion disease-associated mutations in PrP
C did
not inhibit BACE1, and scrapie infected mice brains contained
dramatically higher Ab levels [5], suggesting a loss of PrP
C
function perhaps as a result of PrP
C-PrP
Sc conversion during prion
disease progression.
PrP
C may be a key therapeutic target for sporadic AD, and the
recent report that PrP
C expression was controlled by AICD in a c-
secretase dependent manner [22] presented a potential avenue for
achieving this. Further, a possible feedback model reconciling the
control of APP processing and PrP
C expression in both normal
conditions and in the presence of increased Ab such as that seen in
AD was proposed [36]. Therefore our study was carried out to
further understand the relationship between AICD production
and PrP
C expression. However, utilizing a range of experimental
approaches we found no evidence for AICD involvement in PrP
C
expression. This is despite using a cellular system (N2a cells
expressing APP695) in which we have proven that AICD is
transcriptionally active [19]. If AICD is involved in regulating the
transcription of PrP
C, then the mechanism underlying this is more
complex than that involved in regulating the expression of
neprilysin and is not readily reproduced in cultured cells or
transgenic mice over-expressing human APP. Our findings have
implications for the continued investigation and design of possible
AD therapeutics.
Materials and Methods
Ethics statement
All experimental procedures performed on mice were approved
by the Roslin Institute (University of Edinburgh) Ethical Review
Process Committee and carried out under the UK Home Office
License 60/3478. Human embryonic kidney (HEK) cells were
obtained from the European Collection of Cell Cultures and
Figure 4. Knockdown of APP expression in N2a cells has no effect on PrP
C protein levels. (A) Representative western blots of APP and
PrP
C (antibody 6H4) in N2a cells treated with APP directed siRNA, non-coding control siRNA, and a no RNA transfection control (H2O control), and
subsequent b-actin staining. Approximate molecular weights (kDa) are indicated. (B) Quantification of APP and PrP
C protein levels expressed relative
to the H2O control cells. Data from 3 independent experiments. Statistical analysis by one way ANOVA with Dunnett’s post test comparison to the
H2O control cells, **p,0.01, n.s. not significant.
doi:10.1371/journal.pone.0031754.g004
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Lehmann, Universite ´ Montpellier, France [37].
Cell culture
HEK cells and N2a cells stably over-expressing the human APP
isoforms (APP695, APP751 and APP770), alongside the vector-only
(Hyg), were generated by electroporation as described previously
[19]. Cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Lonza, Basel, Switzerland) containing 10%
(v/v) fetal bovine serum (FBS; Biosera, East Sussex, UK) and 1%
penicillin/streptomycin (Lonza), in a humidified incubator at
37uC, 5% CO2.
APP gene silencing
To ablate endogenous APP expression in the N2a cells, cells
were grown to 80% confluency in growth medium prior to
treatment with 50 nM final concentration of murine APP directed
siRNA, non-coding siRNA or siRNA-free controls following the
manufacturer’s instructions (Thermo Fisher Scientific, Lafayette,
CO, USA). Briefly, sub-confluent cell monolayers were washed
gently with OptiMEM (GIBCO, Invitrogen, Glasgow, UK), before
further incubation in OptiMEM for approximately 30 min (37uC,
5% CO2) during siRNA preparation. A 10 mM siRNA solution in
16 siRNA buffer of either murine APP directed siRNA (ON-
TARGETplus SMARTpool) or non-coding siRNA control (ON-
Figure 5. Inhibition of c-secretase activity does not alter the expression of PrP
C. Representative western blots showing total cell-associated
APP, PrP
C (antibody 6H4) and C-terminal APP fragments (C83/99) in control (2) and DAPT treated (+) HEK (A) and N2a (B) cells, with membrane re-
probing for b-actin. Approximate molecular weights (kDa) are indicated. Quantification of C83/99, APP and PrP
C protein levels in DAPT treated HEK
(C) and N2a (D) cells, expressed relative to control cells (dashed line). Data from 3 (HEK) or 4 (N2a) independent experiments. Statistical analysis by
one way ANOVA with Dunnett’s post test comparison to the control cells, ***p,0.001, **p,0.01, n.s. not significant.
doi:10.1371/journal.pone.0031754.g005
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1 mM in OptiMEM. For the RNA-free control, sterile RNase-free
water was diluted 1:10 in OptiMEM. DharmaFECT Transfection
Reagent-1 was diluted 1:40 in OptiMEM, mixed gently and
incubated for 5 min at room temperature. Equal volumes of the
diluted siRNA/control and DharmaFECT solutions were then
mixed and incubated for 20 min at room temperature, prior to the
addition of 46volumes of OptiMEM containing 10% (v/v) FBS.
The OptiMEM was then removed from the cells, and replaced
with the OptiMEM/FBS/siRNA complexes (or control) for 72 h.
Inhibition of c-secretase
To inhibit endogenous c-secretase activity, HEK or N2a cells
were grown to 90–95% confluency prior to treatment. The cell
monolayer was then washed twice with PBS prior to incubating
the cells in serum-free OptiMEM containing a final concentration
10 mM N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-
butyl ester (DAPT; Sigma-Aldrich, Dorset, UK), or an equal
volume of dimethyl sulfoxide (DMSO, as the control) for 24 h.
Cell lysis, SDS-PAGE and immunoblotting
When confluent and/or after appropriate treatments as
described above, cells were washed twice in phosphate-buffered
saline (PBS with Ca
2+ and Mg
2+; Lonza), harvested by scraping
into PBS, and pelleted at 5006g for 3 min. Cell pellets were lysed
for 30 min on ice in cold lysis buffer (25 mM Tris/HCl, pH7.5,
150 mM NaCl, 5 mM EDTA, 1% (v/v) Triton X-100) containing
Complete
TM protease inhibitor cocktail (Roche, West Sussex,
UK), prior to centrifugation for 5 min at 10006 g. Post-nuclear
supernatants were assessed for total protein content using a
bicinchoninic acid protein assay (Sigma-Aldrich). Cell lysate
containing 50 mg total protein was resolved on 7–17% (APP and
PrP
C) or 16.5% (C83/99) polyacrylamide SDS gel, then electro-
transferred to Hybond-P polyvinylidene difluoride membrane
(PVDF; Amersham Life Sciences, Buckinghamshire, UK). PVDF
membranes were blocked for 1–2 h at room temperature in PBS
containing 0.1% Tween-20 (PBST) and 5% (w/v) skimmed milk
powder, prior to incubation with primary antibody overnight at
4uC. For detection of APP the membrane was incubated with the
monoclonal antibody 22C11 (Millipore, Billerica, MA, USA), and
for detection of PrP
C the membrane was incubated with either the
monoclonal antibody 3F4 (Covance, Princeton, NJ, USA), 6D11
(Eurogentec Ltd, Hampshire, UK) or 6H4 (Prionics, Zurich,
Switzerland), as indicated in the figure legends. For detection of
C83/99, a polyclonal anti-C-terminal APP antibody A8717
(Sigma-Aldrich) was used. After washing off non-specifically
bound primary antibody with PBST, membranes were incubated
in peroxidase-conjugated rabbit-anti-mouse or goat-anti-rabbit
secondary antibodies (Sigma-Aldrich), before further washes with
PBST and detection using enhanced chemiluminescence (Pierce
ECL substrate; Thermo Fischer Scientific). To assess and correct
for protein loading, membranes were stripped at low pH (1% (v/v)
aqueous HCl) for approximately 30 min, re-blocked and probed
with an anti-b-actin antibody (clone AC-15, Sigma-Aldrich) and
the secondary antibody described above. All chemiluminescent
images were captured by a Fujifilm LAS-3000 Intelligent Dark
Box.
Transgenic mice and tissue homogenisation
Animals were obtained from The Jackson Laboratory (Bar
Harbor, ME, USA), and all care was carried out in strict
accordance with institutional guidelines. Transgenic I5 mice (Line
B6.Cg-Tg(PDGFB-APP)5 Lms/J, stock number 004662), which
over-express wild type human APP, and J20 mice (Line B6.Cg-
Tg(PDGFB-APPSwInd)20 Lms/2J, stock number 006293), which
over-express human APP containing the Swedish (K670N/
M671L) and Indiana (V717F) familial AD mutations [23], were
crossed with inbred 129P2 mice, and genotyped to confirm the
APP gene sequence. Brain hemispheres from the I5 (8 weeks old),
J20 (5–9 weeks old) and age-matched non-transgenic littermate
controls were homogenized in 2% (w/v) SDS solution containing
protease inhibitors, and homogenates centrifuged at 100,0006 g
for 1 h at 4uC. The resultant supernatant was assayed for total
protein and assessed for PrP
C and APP protein by SDS-PAGE and
western blotting as described above for cell lysates.
Densitometry and statistical analysis
Quantification and densitometric analyses were carried out
using Image J v1.42q. Within each experiment, data was
normalised to b-actin, and expressed relative to the control
samples. Statistical analyses were performed in GraphPad Prism
v5.03. All quantitative data are expressed as the mean 6 SEM,
unless stated otherwise.
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